GlassScriptPhysician profile
Bruce Brian Beardsley
NPI 1184071730
$6,803.61
in general payments reported to CMS, 2019-2025
23 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,240 · 2022: $827 · 2023: $1,242 · 2024: $1,315 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,531.85 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $559.93 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $518.22 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $484.31 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $383.47 | 2021-2025 | Caplyta |
| Braeburn INC. | $372.68 | 2023-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $352.99 | 2021-2025 | Trintellix |
| Alkermes, INC. | $260.98 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $230.46 | 2021-2025 | Rexulti |
| Indivior INC. | $214.34 | 2021-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $170.31 | 2021-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $158.69 | 2021-2025 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $108.11 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $90.51 | 2021-2022 | |
| Bausch Health US, LLC | $77.83 | 2022-2024 | Aplenzin, Wellbutrin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $71.85 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| E.R. Squibb & Sons, L.L.C. | $64.77 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $43.45 | 2024-2025 | Zurzuvae |
| Almatica Pharma LLC | $36.41 | 2023 | Gralise, Loreev Xr |
| Idorsia Pharmaceuticals US INC | $21.43 | 2023 | Quviviq |
| Corium, LLC | $19.17 | 2024 | Azstarys |
| Orexo US, INC. | $17.27 | 2023 | Zubsolv |
| Supernus Pharmaceuticals, INC. | $14.58 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Beardsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.